




Expression and function of complement- and Toll-like receptors 
in human B cells 
under physiological and autoimmune conditions 






























Doctoral School of Biology 
Immunology PhD Program   




Department of Immunology, Institute of Biology 







Formation of immune complexes (ICs) during ongoing infections represents an 
essential part of the physiological immune response. Complement and Toll-like receptors 
(TLRs) are two effector arms of innate immunity. In addition to generating an immediate 
inflammatory reaction against invading pathogens, the activation of complement and TLRs 
also function to initiate and shape the adaptive immune response. The importance of 
complement- and Toll-like receptors in regulating B cell responses has been demonstrated in 
several autoimmune animal models. However the pathogenic potential of these receptors in 
human autoimmune diseases is still not well-characterized.  
The main goal of my thesis is to gain a better insight into the function of   
complement- and Toll-like receptors and to reveal how they regulate B cell immunity under 
physiological and autoimmune conditions. 
Aims/ I. 
Expression and function of CR1 (CD35) and CR2 (CD21) 
in healthy controls and RA patients 
The functional role of complement receptor type 1 (CR1) and type 2 (CR2) on B cells 
has been demonstrated in several animal models of collagen induced arthritis. Although it has 
been shown that the expression of CR1 and CR2 is lower in the B cells of RA patients, no 
data are available so far regarding the distribution and functions of these complement 
receptors on different B cell subpopulations in autoimmune patients. Our aims were therefore 
 to compare the expression pattern of CR1 and CR2 on CD19+CD27- naive, 
CD19+CD27+ memory B cells and CD19+CD27high plasmablasts of healthy 
individuals and RA patients. 
 to reveal the effect of CR1 clustering on BCR-induced proliferation and antibody 
production of B cells from healthy donors and RA patients. 
Aims/ II. 
Cross-talk between BCR, TLR9 and CR1 
The complement system and TLRs are two effector arms of innate immunity providing a 
first-line host defense against invading pathogens. It is well-established that their separate 
activation functions to initiate and shape the adaptive immune response. However, it is not 
known how the coincidental activation of these two systems influences the final outcome of B 
cell stimulation. Therefore we decided 
 to describe how ligand-induced clustering of CR1 modulates BCR- and/or TLR9-
induced functions of human B cells. 
 to investigate how CR1 clustering affects BCR- and/or TLR9-induced signaling 
events. 
Aims/ III. 
The role of Syk in TLR9-induced signaling of human B cells 
The signal pathway mediated by the engagement of TLR9 classically involves MyD88-
induced NF-κB activation. Although the important role of Syk in immunoreceptor-mediated 
signaling pathways has been established earlier and its role in TLR-associated innate 
immunity has raised attention too, their possible interaction has not been studied yet. 
Therefore 
 we investigated whether Syk can directly be activated in the course of the TLR9 
signaling cascade or not. 
 we analyzed how Syk inhibition affects TLR9-induced functions of B cells and aimed 
to reveal the exact mechanism of CpG-induced Syk activation. 
Methods 
 Isolation of human peripheral and tonsillar B cells 
 Proliferation assay (CFSE and 3H-thymidine incorporation) 
 Cytokine measurement assay (FlowCytomix technology) 
 Plasmablast differentiation (FCM) 
 ELISPOT (Detection of Ig-producing B cells) 
 ELISA (Measurement of Ig-secretion) 
 Flow cytometry (FCM) 
 Fluorescence activated cell sorting (FACS) 
 Laser-scanning confocal microscopy  
 Isolation of human C3 (FPLC method) 
 Western Blot 
 
Results and conclusions/ I. 
CR1 is a potent inhibitor of B cell functions in rheumatoid arthritis patients 
To get a better understanding of the interplay between B cells and the complement system 
in RA, we studied the expression and function of CR1 and CR2 on various B cell populations 
of healthy donors and RA patients.  
 We have found that memory B cells of healthy individuals and active RA patients 
express significantly higher levels of CR1 than naive B cells. In contrast to this, the 
appearance of CR2 decreases during differentiation to memory cells, proving that 
these two receptors are regulated in a different manner in human B cells. Confirming 
earlier results we also detected a significant reduction in the level of CR1 and CR2 on 
human plasmablasts. We have clearly demonstrated that the differences in receptor 
expression between healthy individuals and RA patients are not caused by the 
different frequencies of the various B cell subpopulations and it does not correlate 
with disease activity. 
 We have shown that clustering of CR1 inhibits BCR-induced B cell proliferation as 
well as antibody production dose-dependently. Despite the significant decrease of CR1 
expression in active RA patients, the inhibitory capacity of this complement receptor 
is preserved, and its ligand-induced clustering results in a significant inhibition of B 
cell functions – similarly to that found in the case of healthy individuals. 
These functional results together with the expression data suggest that CR1 and CR2 have 
opposite effects on human B lymphocytes and they play an important role in the IC-mediated 
fine tuning of B cells’ function both under physiological and pathological conditions. 
 
Results and conclusions/ II. 
CR1 clustering inhibits TLR9-induced proliferation and cytokine production of human 
B cells, but does not affect their plasmablast differentiation 
 
Studying the effect of the coincidental activation of complement- and Toll-like receptors 
on the final outcome of B cells’ functions we obtained the following results. 
 We have revealed that CR1 inhibits not only the BCR-induced activation of human B 
lymphocytes, but it also has a regulatory effect on TLR9-initiated B cell functions. 
Ligation of CR1 exerts a dose-dependent inhibition on the CpG-induced B cell 
proliferation as well as on cytokine production. 
 We have proven that ligation of CR1 does not affect the TLR9-induced differentiation 
of B cells, but strikingly, its clustering results in elevation of plasmablast formation 
induced by the simultaneous triggering of BCR- and TLR9. 
 We have demonstrated for the first time that clustering of CR1 results in 
dephosphorylation of key signaling molecules, such as Syk and MAPKs, thus it is able 
to interfere with the BCR- and TLR9-mediated signals at an early stage of B cell 
activation. 
These results give evidence of the negative control of TLR9-induced signaling in B cells 
by CR1. We identified a new point of intersection where the complement system and TLRs 




Results and conclusions/ III. 
Syk is indispensable for CpG-induced activation and differentiation of human B cells 
Studying the role of Syk in TLR9-induced activation of human B cells we obtained the 
following results. 
 We have found that beside the "classical", MyD88-mediated signaling pathway, CpG 
induces dose- and time-dependent phosphorylation of Syk in resting human tonsillar B 
cells. We have demonstrated that this phosphorylation is initiated from the cell surface 
and does not occur via the cell surface BCR. 
 Our data prove that activation of Syk is indispensable for the most important CpG-
driven B cell functions, since treatment of the cultured cells with Syk inhibitors results 
in a strong and dose-dependent decrease of the CpG-induced proliferation as well as 
cytokine and antibody production. 
 We have shown for the first time that the BCR- and CpG-mediated signaling pathways 
already converge as early as the level of Lyn and Syk in human B cells. 
 We have demonstrated that engagement of the CpG binding sites on the cell surface 
leads to the activation of the membrane proximal Lyn followed by Syk and pp38 in 
human B cells in a MyD88 (TLR9)-dependent manner. 
 We have given evidence that the CpG-induced Syk activation is a prerequisite for the 
delivery of CpG oligonucleotides into TLR9-containing endolysosomes and for the 
induction of TLR9 expression, allowing efficient propagation of TLR9-mediated 




In conclusion, our results suggest that under physiological conditions CR1 clustering 
has a negative regulatory effect on both BCR- and TLR9-dependent functions of B cells 
by the induction of dephosphorylation of membrane proximal kinases (such as Syk) at an 
early stage of B cell activation. 
We have shown that the decreased expression of CR1 in RA patients does not 
influence the receptor’s inhibitory function, thus CR1 can be considered as a potential 
therapeutical target in rheumatoid arthritis. The inhibitory function of CR1 could be 
especially important in the treatment of IC-mediated autoimmune diseases, where high 
overload of self-RNA and DNA-containing ICs may lead to aberrant B cell activation by 
the simultaneous engagement of both BCR and TLR9. 
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